Asymptomatic and symptomatic cardiac toxicity associated with immune checkpoint inhibitors: insights from a Japanese registry
Open Access
- 15 May 2026
- journal article
- Published by Oxford University Press (OUP) in European Heart Journal Open
- Vol. 6 (3) , oeag079
Abstract
Aims: Immune checkpoint inhibitors (ICIs) are a cornerstone of cancer therapy; however, immune-related adverse events, including myocarditis, pose significant challenges. Furthermore, limited data exist on the pathology of mild or asymptomatic cases. This study aimed to characterize the clinical, biomarker, and pathological features of ICI-associated cardiac toxicity, comparing symptomatic and asymptomatic cases within a Japanese multicentre registry. Methods and results: A nationwide, retrospective registry collected data from 90 patients across 23 hospitals between 2020 and 2022. Patients were classified according to the American Society of Clinical Oncology Clinical Practice Guidelines: Grade 1 (asymptomatic) and Grades 2–4 (symptomatic). Endomyocardial biopsy was performed in 24 patients (n = 19 symptomatic, n = 5 asymptomatic). Among the enrolled patients (mean age: 68 years; 76.7% male), 41.1% were classified as Grade 1, whereas 58.9% were symptomatic (Grades 2–4). Symptomatic cases exhibited significantly higher troponin I and creatine kinase levels at onset. Pathological analysis revealed more extensive lymphocytic infiltration (CD3+ T cells) in symptomatic cases, particularly with higher CD8+ and CD68+ cell counts. Continuation of ICI therapy was more frequent in the asymptomatic group, and only one patient experienced recurrence. In contrast, all seven myocarditis-related deaths occurred in symptomatic patients. Conclusion: This study provides one of the largest pathological and biomarker-based comparisons of symptomatic and asymptomatic ICI-associated cardiac toxicity. Our findings suggest that asymptomatic cases may represent a distinct, less aggressive inflammatory phenotype, characterized by lower CD8+ infiltration and limited myocardial damage.Keywords
Funding Information
- Japan Agency for Medical Research and Development (JP 20ck0106633h0001)
- Japan Agency for Medical Research and Development (21ck0106633h0002)
This publication has 29 references indexed in Scilit:
- Elevations of Cardiac Troponin in Patients Receiving Immune Checkpoint InhibitorsJACC: Advances, 2024
- Cardiovascular Toxicities of Immune Therapies for Cancer – A Scientific Statement of the Heart Failure Association (HFA) of the ESC and the ESC Council of Cardio-OncologyEuropean Journal of Heart Failure, 2024
- Management of toxicities from immunotherapy: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-upAnnals of Oncology, 2022
- Routine assessment of cardiotoxicity in patients undergoing long-term immune checkpoint inhibitor therapyHeart and Vessels, 2022
- Myocardial T1 and T2 Mapping by Magnetic Resonance in Patients With Immune Checkpoint Inhibitor–Associated MyocarditisJACC, 2021
- Global Longitudinal Strain and Cardiac Events in Patients With Immune Checkpoint Inhibitor-Related MyocarditisJACC, 2020
- Myocarditis following the use of different immune checkpoint inhibitor regimens: A real-world analysis of post-marketing surveillance dataInternational Immunopharmacology, 2019
- Fatal Toxic Effects Associated With Immune Checkpoint InhibitorsJAMA Oncology, 2018
- Myocarditis in Patients Treated With Immune Checkpoint InhibitorsJACC, 2018
- Quantification of leucocytes, T-lymphocytes and macrophages in autoptical endomyocardial tissue from 56 normal human hearts during the first year of lifeForensic Science International, 2016